Steven M Dubinett
Overview
Explore the profile of Steven M Dubinett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
6083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzilli S, Rahal Z, Rouhani M, Janes S, Kadara H, Dubinett S, et al.
Nat Rev Cancer
. 2025 Feb;
PMID: 39994467
Over the past decade, substantial progress has been made in the development of targeted and immune-based therapies for patients with advanced non-small-cell lung cancer. To further improve outcomes for patients...
2.
Zhao X, Liu B, William W, Tsanov K, Ho Y, Barriga F, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39725169
Introduction: Copy-number (CN) loss of chromosome 9p, or parts thereof, impair immune response and confer ICT resistance by direct elimination of immune-regulatory genes on this arm, notably IFNγ genes at...
3.
Oh M, Dumitras C, Salehi-Rad R, Tran L, Krysan K, Lim R, et al.
Mol Cancer Ther
. 2024 Nov;
24(2):286-298.
PMID: 39559833
The treatment of non-small cell lung cancer has made major strides with the use of immune checkpoint inhibitors; however, there remains a significant need for therapies that can overcome immunotherapy...
4.
Moghaddam S, Savai R, Salehi-Rad R, Sengupta S, Kammer M, Massion P, et al.
Am J Respir Crit Care Med
. 2024 Aug;
210(5):548-571.
PMID: 39115548
Despite significant advances in precision treatments and immunotherapy, lung cancer is the most common cause of cancer death worldwide. To reduce incidence and improve survival rates, a deeper understanding of...
5.
Hong A, Piva M, Liu S, Hugo W, Lomeli S, Zoete V, et al.
Cancer Discov
. 2024 Jul;
14(7):1357.
PMID: 38946326
No abstract available.
6.
Li S, Li W, Liu B, Krysan K, Dubinett S
Cancer Res Commun
. 2024 Jun;
4(7):1738-1747.
PMID: 38856716
Significance: This study explores the use of cfDNA methylomes for the classification of lung cancer subtypes, vital for effective treatment. By identifying specific methylation markers in tumor tissues, we developed...
7.
Purbey P, Seo J, Paul M, Iwamoto K, Daly A, Feng A, et al.
Cell Rep
. 2024 Jun;
43(6):114289.
PMID: 38833371
Type I interferon (IFN-I) and IFN-γ foster antitumor immunity by facilitating T cell responses. Paradoxically, IFNs may promote T cell exhaustion by activating immune checkpoints. The downstream regulators of these...
8.
Stackpole M, Zeng W, Li S, Liu C, Zhou Y, He S, et al.
Nat Commun
. 2024 May;
15(1):3693.
PMID: 38693151
No abstract available.
9.
Lim R, Salehi-Rad R, Tran L, Oh M, Dumitras C, Crosson W, et al.
Cell Rep Med
. 2024 Mar;
5(4):101479.
PMID: 38518770
Immune checkpoint blockade (ICB) with PD-1/PD-L1 inhibition has revolutionized the treatment of non-small cell lung cancer (NSCLC). Durable responses, however, are observed only in a subpopulation of patients. Defective antigen...
10.
Han G, Sinjab A, Rahal Z, Lynch A, Treekitkarnmongkol W, Liu Y, et al.
Nature
. 2024 Mar;
628(8006):E1.
PMID: 38499683
No abstract available.